As we mentioned in a previous blog post, after November 27, 2019, all U.S. wholesalers – including the “Big 3” pharmaceutical distributors that handle most of the drug distribution in the United States (Cardinal Health, McKesson, and AmerisourceBergen) – must verify serialized products upon a request for saleable returns, per the DSCSA.
For a variety of reasons, OPTEL has chosen to implement the MediLedger Verification Router Service (VRS) developed by Chronicled to meet this timeline. First, MediLedger provides connectivity to all VRS providers, which will facilitate a seamless transmission of verification requests. Second, we have worked with the MediLedger team to integrate their solution into OPTEL’s Verify Platform, so our customers don’t have to do anything besides upgrade their software. Finally, the MediLedger solution complies with GS1 standards for product verification, which improves the interoperability of pharmaceutical supply chains.
Our work implementing the VRS is well underway. OPTEL is an active part of industry-wide VRS testing, and we have already had several successful tests with other MediLedger partners and other VRS providers, such as rfXcel. In July 2019, Mediledger presented a working demo of the VRS to the DSCSA working group, which included Cardinal Health, McKesson, and AmerisourceBergen as well as major pharmaceutical manufacturers.
We expect our work with MediLedger will deliver an effective VRS to meet the DSCSA saleable returns requirements by November 2019.